<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311610</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-80402</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CALGB-80402</secondary_id>
    <secondary_id>CDR0000467234</secondary_id>
    <nct_id>NCT00311610</nct_id>
  </id_info>
  <brief_title>Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as liposomal SN-38, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well liposomal SN-38 works in treating patients&#xD;
      with metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective response rate following treatment with SN-38 liposome as a&#xD;
           second-line treatment in patients with metastatic colorectal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the proportion of patients treated with this drug who experience any grade 3&#xD;
           or greater toxicity.&#xD;
&#xD;
        -  Determine progression-free survival and overall survival for patients treated with this&#xD;
           drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>q 2 cycles during tx</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>q cycle during tx</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>SN-38 liposome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
After completion of study treatment, patients are followed every 3 months for up to 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SN-38 liposome</intervention_name>
    <description>38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression</description>
    <arm_group_label>SN-38 liposome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically determined metastatic colorectal cancer*&#xD;
&#xD;
               -  Primary lesion confirmed endoscopically, surgically, or radiologically NOTE: *&#xD;
                  Patients with a history of colorectal cancer treated by surgical resection who&#xD;
                  develop radiological or clinical evidence of metastatic cancer do not require&#xD;
                  separate histological or cytological confirmation of metastatic disease, unless&#xD;
                  more than 5 years between primary surgery and development of metastatic disease&#xD;
                  OR primary cancer was stage I&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
             conventional techniques OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Nonmeasurable lesions include the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  UGT1A1*1 homozygous or UGT1A1*28 heterozygous genotype status&#xD;
&#xD;
               -  Patients with homozygous UGT1A1*28 genotype not eligible&#xD;
&#xD;
          -  Received at least 1 prior regimen with oxaliplatin for metastatic disease&#xD;
&#xD;
          -  Recurrent disease following prior adjuvant therapy allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception duration and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No known Gilbert's disease or other chronic liver disease&#xD;
&#xD;
          -  No colonic or small bowel disorders (e.g., inflammatory bowel disease, Crohn's&#xD;
             disease, or ulcerative colitis) that predispose the patients to uncontrolled diarrhea&#xD;
             (i.e., &gt; 3 watery or soft stools daily at baseline in patients without a colostomy or&#xD;
             ileostomy)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No prior irinotecan&#xD;
&#xD;
          -  Prior pelvic radiotherapy allowed as long as measurable lesion is outside irradiated&#xD;
             field&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent steroids except those given for adrenal failure, hormones for&#xD;
             non-disease-related conditions (e.g., insulin for diabetes), or intermittent&#xD;
             dexamethasone as an antiemetic or for prevention of infusion reaction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allyson Ocean, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Office -Vandever Medical Office</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tunnell Cancer Center at Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Cancer Program at Union Hospital</name>
      <address>
        <city>Elkton MD</city>
        <state>Maryland</state>
        <zip>21921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Cooper - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ocean AJ, Niedzwiecki D, Atkins JN, et al.: LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: results of CALGB 80402. [Abstract] J Clin Oncol 26 (Suppl 15): A-4109, 2008.</citation>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2006</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

